Elacestrant Clinical Trials
15 recruitingDrug
Phase 29Phase 17Phase 33
Showing 1–15 of 15 trials
Recruiting
Phase 1Phase 2
ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
Breast CancerMetastatic Breast CancerBreast Cancer Female+2 more
Sarah Sammons, MD65 enrolled1 locationNCT07198724
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Phase 3
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Advanced Breast Cancer
MedSIR240 enrolled99 locationsNCT06382948
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled533 locationsNCT06492616
Recruiting
Phase 2
Circulating Tumor DNA
ER+ Breast Cancer
Yale University50 enrolled7 locationsNCT06923527
Recruiting
Phase 1Phase 2
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma95 enrolled14 locationsNCT05573126
Recruiting
Phase 1
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Metastatic Breast CancerAdvanced Solid TumorAdvanced Breast Cancer
BeiGene300 enrolled63 locationsNCT06120283
Recruiting
Phase 2
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Endometrial Cancer
Memorial Sloan Kettering Cancer Center75 enrolled7 locationsNCT07209449
Recruiting
Phase 2
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Ductal Carcinoma in Situ
QuantumLeap Healthcare Collaborative400 enrolled27 locationsNCT06075953
Recruiting
Phase 1
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Advanced Breast Cancer
Stemline Therapeutics, Inc.240 enrolled30 locationsNCT06638307
Recruiting
Phase 2
PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Kristina A. Fanucci297 enrolled1 locationNCT07222215
Recruiting
Phase 1Phase 2
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Breast CancerMetastatic Breast Cancer
Stemline Therapeutics, Inc.435 enrolled118 locationsNCT05563220
Recruiting
Phase 1
Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer
HER2-negative Breast CancerBreast Cancer Metastatic Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute18 enrolled1 locationNCT06691035
Recruiting
Phase 2
A Short-term Preoperative, Evaluating Activity and Safety of Elacestrant Monotherapy as Compared to Elacestrant + Ovarian Function Suppression (LHRH Agonist) in Premenopausal Patients With Stage I-II ER+/HER2- Breast Cancer
Breast Cancer
Gustave Roussy, Cancer Campus, Grand Paris140 enrolled1 locationNCT07159451
Recruiting
Phase 3
Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)
European Organisation for Research and Treatment of Cancer - EORTC220 enrolled94 locationsNCT05512364